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Abstract
OBJECTIVE: This study was designed to characterize the reproducibility of measurement for tumor volumes and
their longest tumor diameters (LDs) and estimate the potential impact of using changes in tumor volumes instead
of LDs as the basis for response assessments. METHODS: We studied patients with advanced lung cancer who
have been observed longitudinally with x-ray computed tomography in a multinational trial. A total of 71 time points
from 10 patients with 13 morphologically complex target lesions were analyzed. A total of 6461 volume measure-
ments and their corresponding LDs were made by seven independent teams using their own work flows and im-
age analysis tools. Interteam agreement and overall interrater concurrence were characterized. RESULTS:
Interteam agreement between volume measurements was better than between LD measurements (ι = 0.945 vs
0.734, P = .005). The variability in determining the nadir was lower for volumes than for LDs (P = .005). Use of
standard thresholds for the RECIST-based method and use of experimentally determined cutoffs for categorizing
responses showed that volume measurements had a significantly greater sensitivity for detecting partial responses
and disease progression. Earlier detection of progression would have led to earlier changes in patient management
in most cases. CONCLUSIONS:Our findings indicate that measurement of changes in tumor volumes is adequately
reproducible. Using tumor volumes as the basis for response assessments could have a positive impact on both
patient management and clinical trials. More authoritative work to qualify or discard changes in volume as the basis
for response assessments should proceed.
Translational Oncology (2012) 5, 19–25
Introduction
X-ray computed tomography (CT) is often an effective imaging tech-
nique for assessing responses to treatment in patients with solid tumors.
Qualitative impressions based on nothing more than visual inspections
of the images are frequently sufficient for making major clinical man-
agement decisions. However, quantification becomes more crucial
when treatment effects are not robust, for example, when tumor masses
change only slowly over the course of illness or when the differences
between two arms of a clinical trial are not large. The need to distin-
guish between measurement noise and small but biologically true
changes in health status becomes particularly important when options
exist for patients who are not responding adequately to their current
therapeutic regimens. Ethically, these patients deserve access to alterna-
tives as soon as confidence emerges that their current regimens are fu-
tile. Scientifically, objective radiologic evidence might be the best way
to evaluate the effectiveness of investigational treatments whenever pa-
tients will switch to new therapeutic regimes, which will then confound
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the use of survival time as an end point by exerting new, off-study in-
fluences on the course of their illness. In short, the field needs more
sensitive measures of response [1], so do all of the other stakeholders
in the treatment of individual patients with cancer [2]. Expensive ther-
apeutic regimens would be more cost effective if they were stopped just
as soon as evidence of futility emerged.
Most assessments rely on the Response Evaluation Criteria in Solid
Tumors (RECIST) [3]. The current standard of care uses electronic
calipers to measure a single, in-plane line length, the longest diameter
(LD), as a proxy for the mass of a tumor. Simple measures of LD can
be adequate [4,5]. Using LDs has advantages, including simplicity
and the widespread access of health care workers to measurement tools
that require very little technical training to use. However, concerns
about the precision, accuracy, and sensitivity of using LDs as a quan-
titative measurement of tumor mass have been raised [6,7].
Some of these concerns could be addressed by semiautomated im-
age analysis algorithms. For example, the RECIST 1.1 Work Group
alluded to a future state in which the variability in tumor measurements
could be decreased by “software tools that calculate the maximal diam-
eter for a perimeter of a tumor” [8]. In theory, demarcating the bound-
ary of a mass on every slice that it is visible, and then interrogating every
slice to find the greatest distance between any two in-plane pixels, could
improve both repeatability and reproducibility. It could eliminate some
of the subjectivity in selecting the sole slice for measurement, decrease
the judgment associated with how to draw the line, and reduce some of
the factors that regulatory authorities have noted can adversely influ-
ence the placement of the calipers tips, such as display contrast, ambient
room light, viewing angle, and others [9]. Moreover, although automa-
tion might not eliminate the variability associated with selecting the
edge between neoplastic and normal tissue, it could stabilize the bias
over time to facilitate the assessment of change. However, questions
would still remain about how well any single line reflects the true tumor
burden, particularly when the geometries of tumor masses are complex.
Many investigators have suggested that measuring the volume of
the whole tumor could solve some of these problems and have clini-
cally significant effects on patient management [10,11]. Indeed, a few
studies have shown that volumetric image analysis (VIA) can add value
[12,13]. However, technical problems have delayed the adoption of
VIA [14]. Historically, substantial amounts of effort in time and man-
power have been required for VIA. And some reports about the pre-
cision [15–18] and accuracy [19] of volume measurements have led
to concerns that variability in volume measurements can be mistaken
for medically meaningful changes, leading to errors in management.
Recent assessments of VIA technology are more optimistic [20].
One reported suggested that intrarater and interrater variability can
be as little as 1% when analyzing well-demarcated tumors with simple
geometric shapes in a single image set [21]. For more complex tumors,
new algorithms can produce intrarater and interrater measurements of
change with reliabilities of about ±5% on serially acquired image sets
[22]. For patients with advanced lung cancer, within-subjects pairs of
image sets acquired after very short time intervals in recent “coffee
break” studies showed that short-term reproducibility was increased
to 95% confidence intervals of about ±15%, provided that the masses
were not too small [23]. If such a high level of reproducibility can be
regularly achieved, then for many tumor morphologies, VIA would be
substantially more sensitive than the current practice of using rela-
tively large changes in LDs.
As encouraging as these results are, they do not directly address the
question of whether VIA is a better method than LDs or automated
measurements for managing individual patients with lung cancer or
for making decisions in clinical trial settings. Also, most studies com-
paring the precision of LDs to VIA were done within single centers,
were limited to three or fewer image analysts, and used manually placed
electronic calipers to measure LD [11–14]. Accordingly, our investiga-
tion was designed as a proof-of-concept study. We conducted a head-
to-head comparison between semiautomated diameter measurements,
called auto-LDs, and VIA. We worked with a small subset of the data
from a multinational clinical trial of an investigational new drug in
which image quality tends to be variable and often less than ideal
[24]. In conformance with current standards for evaluating novel diag-
nostic technologies [25], value was defined as the theoretical potential
for a method to have a unique and meaningful effect on clinical trials or
on individual patient management. Measurements were made to sup-
port or disprove several key hypotheses, which included these negative
claims: (1) interrater reliability is higher for auto-LDs than whole tumor
volumes, (2) VIA fails more often than auto-LDs because not all tumors
have adequately demarcated boundaries on every slice, and (3) VIA
increases costs, effort, and the amount of time required to analyze the




The Quantitative Imaging Biomarker Alliance (QIBA) [26,27]
constructed a “process map” [28] for either qualifying or discarding
VIA as a useful method for improving the standard of care for patients
with advanced stage lung cancer. This study was only one of many
groundwork projects described by the qualification process map.
Patients
Seventy-one time points from 10 cases were retrospectively selected
from a sample of 253 patients with stage IIIb or IV, non–small cell
lung cancer. These subjects had volunteered to participate in a ran-
domized, double-blind, clinical trial conducted at about 70 sites
worldwide. They were all treated with a doublet chemotherapy regi-
men that represented the then current standard of care for years 2007
to 2009. They were then randomized to receive either an investiga-
tional new drug or placebo along with the doublet. The cases were
selected from an imaging-only archive in the chronological order of
their enrollment if, and only if, they had five or more analyzable CT
scans after their baseline scan. No other information was known at the
time of selection or ever made available to the image analysts.
CT Scans
Because the study was conducted at about 70 different sites world-
wide, the image acquisition technique used the local standard of care
as starting point for performing the scans. Then, the imaging man-
uals specified that all scans had to be acquired and processed with
parameters that led to single breath hold images of the chest with
reconstruction intervals of 5 mm or less without gaps. Sites were
strongly encouraged, but not absolutely required, to use the same
machine and identical image acquisition parameters each time they
scanned their patients.
Target Lesions
Tumors were preselected as target lesions for this pilot study of
technical feasibility if, and only if, they were predominantly in the
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lung. The project manager assembled and distributed screenshots
of the target lesions, which were marked up on only one slice of
the baseline scan in PowerPoint slide format.
Image Analysts
The QIBA workforce for this particular project came from a diverse
group with expertise in image processing and analysis, including two
imaging CROs, an imaging device manufacturer, two image analysis
software development companies, an academic cancer center, and a
biopharmaceutical company.
The workforce was given no study-specific training or instructions
other than to quantify the volumes of the marked tumors at each
time point and semiautomatically generate the corresponding LDs.
The “auto-LD” was predefined as the greatest in-plane distance be-
tween two pixels on the edges making up the boundaries around the
tumor in the whole stack of tomographic images on which the target
lesion was visible. Once the project began, there was no communi-
cation between any of the image analysis teams or any feedback from
QIBA or the project manager.
Image Analysis
The sponsor and one software development company used the
same image analysis tool. All of the other analyses were conducted
with different tools that had been developed by the parent organiza-
tions of the analysts. All of the software tools deployed semiautomatic
edge detection algorithms of one type or another. An operator could
constrain or extend the boundaries as judgment indicated. Practicing
radiologists supervised the analyses for the two CROs and the aca-
demic site. The remainder relied exclusively on analysts with no for-
mal medical practice credentials.
All results were finalized by the individual image analysis teams,
and then forwarded to the project manager, who summed the mea-
sures for patients with more than one target lesion, deidentified the
image analysts, and then distributed the end points for statistical anal-
ysis. The two end points were the sum of LDs (auto-SLDs) for each
marked target lesion and the corresponding sum of tumor volumes at
each time point.
Statistical Analyses
For the purpose of simulation, an assumption was made that the
date of the baseline scan corresponded to the day treatment started,
and the last scan corresponded to the day the subject came off trial.
All statistical analyses were conducted in with a commercially avail-
able software packaged called “R.” Overall interrater agreement was
assessed using the ι measure of agreement of Janson & Olsson. Individ-
ual interrater agreement was assessed using the concordance correlation
coefficient. Interrater variability was assessed through (1) the coefficient
of variation (CV) of the volumes per time point and (2) the SD of the
differences between each postbaseline time point measurement and the
baseline measurement divided by the baseline value.
The null hypothesis of equal variance with respect to determining
the nadir of measurements with VIA or auto-SLD was assessed using
Levene test. For the test, the difference between time to nadir for each
patient and rater and the average time to nadir for each patient using
the same type of measurement were used.
In an attempt to perform a fair comparison between VIA and
auto-SLD, an analogous strategy of constructing categorical response
variables was used for determining volumetric changes and disease
progression. A negative change from baseline was used to define a
partial response (PR), and a positive change from the nadir was used
to declare progressive disease (PD). Volumetric thresholds for categor-
ical responses were based on RECIST 1.1 thresholds and also were
determined experimentally based on results for interrater reliability.
Experimentally based thresholds were constructed by determining
the SD of measurement among all image analysts. Cutoffs for PD
and PR were then set symmetrically as ±2SD, respectively. For the
auto-SLDs, RECIST 1.1 values were used. A 30% or greater decrease
in the auto-SLD defined PR, whereas an increase of 20% or more
defined PD.
Both time to PR as well as the theoretical progression-free survival
(PFS) interval were measured. Results were computed for each image
analysis team independently and then recalculated for pooled data
from all teams.
Differences between the average auto-SLD values and average
volumetric measurements were assessed using the log-rank test.
To identify and quantify systematic biases among image analysis
teams and understand how they relate to each other, a hierarchical
clustering based on average linkage was performed. A quantitative
dendrogram, or tree diagram, was constructed [29]. The dendrogram
was designed to show the arrangement of the clusters. It was con-




All 10 subjects included in the analysis met diagnostic criteria for
stage IV lung cancer. The mean time between the baseline scan and the
last scan was 289 ± 64 days (median = 274 days, range = 213-391 days).
Patients were scanned an average of 7.3 ± 1.4 times (median = 7 times,
range = 6-10 times).
Characteristics of the Target Lesions
There was general agreement among teams that the target lesions
were quite difficult to assess. Subjectively, there was incomplete con-
fidence in the placement of some indistinct boundaries, particularly
where masses wrapped around blood vessels, invaded the mediastinum,
or were colocated with other pulmonary pathology, such as collapsed
lung segments and effusions. Qualitatively, many of the target lesions
appeared spiculated and asymmetrically lobulated, whereas 70% were
attached to the pleura. Figure 1 shows typical examples.
A total of 6461 measurements of tumor volume and 6461 measure-
ments of their corresponding LDs were made by the seven indepen-
dent image analysis teams.
Using data from all teams showed that at baseline, the 13 total
target lesions in this sample had an average sum of LDs (auto-SLD)
of 6.6 ± 3.1 cm (median = 7.4 cm, range = 2.2-11.3 cm). During the
entire study, the average auto-SLD from all 71 time points was 5.3 ±
2.2 cm (median = 5.3 cm, range = 2.1-11.3 cm).
Using data from all teams showed that at baseline, the target
lesions in this sample had an average per patient volume of 106 ±
125 mL (median = 63 mL, range = 1.7-395 mL). During the entire
study, the average per patient volume from all 71 time points was 42 ±
58 mL (median = 23 mL, range = 1.8-394 mL).
Technical Performance: Precision of Measurement
For auto-SLD measurements, the ι value describing overall inter-
rater agreement was 0.734. Individual interrater agreement described
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by the concordance correlation coefficients varied between 0.58
and 0.96.
For the sum of volumes, overall interrater agreement was higher, as
measured by an ι of 0.945. Individual interrater agreement described by
the concordance correlation coefficients varied between 0.86 and 0.993.
Analyzing the agreement between absolute volumes at face value
showed a mean CV of 25% and an upper 95% confidence interval
on the CV of 59%. However, once normalized to baseline, the find-
ings showed that differences between image analysis teams had an SD
of only 12.4% (95%CI = −21.3% to 31.5%).When considering only
measurements at which the time point volume was less than the base-
line volume, the SD between image analysis teams was only 8.6%
(95% CI = −16.7% to 18.7%). The overall dynamic range showed
an SD from baseline of 39.9% (95% CI = −94.2% to 55.3%).
For auto-SLD data, the mean CV was 16.1% (upper 95% CI =
44.9%). After baseline normalization, the difference from average
had an SD of 7.2% (95% CI = −14.1% to 13.5%) and the dynamic
range an SD of 18.3% (95% CI = −63.1% to 12.9%).
Concordance Defining the Nadir
Examining the auto-SLD measurements showed that there were
no cases in which all image analysis teams agreed on the exact time
point that corresponded to the lowest value. There were two cases
where the discrepancy was within only one time point, so that only
two time points described the nadir, and four others where the dis-
crepancy was within ±1 time point, so that three time points described
the nadir. In one case, one team measured the nadir at baseline.
Another team measured the nadir at the very last time point, which
corresponded to the fifth postbaseline scan. Every time point from
baseline to the end of treatment was selected as the nadir by at least
one team. Taking the extreme values for all the cases showed that the
maximum discrepancy per subject averaged 136 ± 70 days (median =
121 days, range = 56-291 days).
For volume measurements, there were two cases in which all seven
of the image analyst teams agreed on the exact time point that corre-
sponded to the volumetric nadir. The variance was one time point in
two cases, and ±1 time points in the other six cases. These variances
corresponded to relatively small changes in tumor volume in the mid-
dle of treatment, that is, at the bottoms of the wells of “U”-shaped
response curves. Taking the extreme values showed that the maximum
discrepancy per subject averaged 61 ± 39 days (median = 84 days,
range = 0-97 days).
Variability in determining the time to the nadir with volume mea-
surements was less than with auto-SLD measurements (P = .005; two-
sided P value, Levene test).
Effect on Best Overall Response
The average auto-SLD values showed that, while on the trial, only
3 of the 10 patients would have met RECIST criteria for a PR.
For volumes, using 2 SDs as a criterion for change produced a
threshold for PR of just less than a 25% decrease in volume. At a
threshold that required more than 25% reduction in volume for the
assessment of PR, VIA showed that 9 of the 10 patients met criteria
for PR. If the threshold had required a change of more than 33%, then
8 of the 10 patients would have met criteria for PR. In one patient,
tumor size continuously increased at every time point. In the nine
others, the volume of the nadir was less than the volume of the baseline
by a mean of 59% (median = 55%, range = 33%-95%).
Figure 2 shows the Kaplan-Meier curves for time to PR. Using the
results of the log-rank test, we rejected the null hypothesis of no
difference in time to PR by the average of the auto-SLD versus the
average of the volumetric analysis (P = .004; two-sided P value, exact
log-rank test).
Influence on PFS
Auto-SLD values for the selected target lesions showed that only
4 of the 10 subjects would have ever met RECIST criteria for PD
while on trial.
Using the previously established threshold for change, that is, a
greater than 25% increase in volume to declare PD, VIA showed that
8 of the 10 would have met criteria for PD, with an average increase
from the nadir of 93% (median = 75%, range = 38%-242%). In one
case, both SLDs and volumes suggested that the selected target lesions
were continuously decreasing in size at every time point. In the other
case, where all analysts agreed that the tumor burden increased after
an initial response, three teams found increases of more than 25%,
whereas four teams reported increases ranging from only 7% to
12%. The seven-team average was 14.7%.
In one case, the average auto-SLD values met RECIST criteria for
PD at the same time as VIA. In all other cases, VIA showed PD before
auto-SLD.
In eight of the nine cases where the target lesions increased in size dur-
ing the trial, using volumes would have decreased RECIST defined PFS
by an average of 62 ± 47 days (median = 42 days, range = 0-144 days).
Figure 3 shows the Kaplan-Meier curves for PFS. Based on the
log-rank test for the whole sample, we rejected the null hypothesis
of no difference between average volumes and average auto-SLD
(P = .02; two-sided P value, exact log-rank test).
Systematic Biases
Hierarchical clustering of all quantitative measurements revealed that
biases among the image analysis teams were consistent for measurements
Figure 1. Typical mass. All patients in this sample had stage IV
non–small cell lung cancer. Many of the target lesions were
morphologically complex and associated with comorbid pulmo-
nary disease.
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of both volumes and auto-SLDs. For example, one image analysis team
produced estimates of absolute volumes that were lower than the median
97% of the time, whereas their corresponding auto-SLD measurements
were lower than the median 85% of the time. In contrast, another team
produced estimates that were higher than or equal to the median 85% of
the time for volumes and 82% of the time for auto-SLD. The image
analysis teams that were supervised by expert radiologists consistently
clustered in either the highest- or the lowest-volume groupings, whereas
those teams without expert radiologist supervision consistently clustered
together in the middle.
Although an auditable trail of the time required was not kept, all of
the teams estimated that it took between 5 and 20 minutes to import
the images and export the results, depending on lesion complexity.
Discussion
The results show that there is at least one context in which volumes
outperform auto-SLDs as the input measurement for RECIST-based
assessments. In this population, which had geometrically complex
tumors and comorbid pulmonary disease, changes in volumes were
more consistently measured at all time points than were their
corresponding auto-SLDs. As a consequence, volumes were more sen-
sitive for detecting favorable tumor responses as well as for diagnosing
disease progression. A majority of the patients who had to be right
censored at the time they came off trial because their auto-SLDs never
extended beyond the stable disease range would have been reclassified
if volumes had been used as the basis for their response assessments.
In our attempt to determine whether measuring tumor volumes
can add more value than estimating the LDs, we felt compelled to
use the standard range for auto-SLDs established by RECIST. How-
ever, for the new measure of volumes, we allowed the data to deter-
mine the threshold for distinguishing between measurement noise
and a likely change in health status. In this sample, a change in the
sum of tumor volumes that was greater than 25% carried only a 2.5%
risk of incorrectly diagnosing PD. This seems like an acceptable level
of risk for patients with other options for treatment. Using a threshold
of 30% would not have changed the results. Using a threshold of 40%
would not have changed the conclusions. It seems plausible to assume
that the threshold for having adequate confidence in the volume mea-
surements will need to be reanalyzed in many different contexts and
may vary with the type of tumor being treated. The thresholds we
found for changes in tumor volume in this sample do not challenge
the thresholds described by RECIST for LDs. These target lesions
were geometrically complex. Simple extrapolations between three di-
mensions and one dimension are known to work well in some situa-
tions where tumor morphology is simple but would be precarious in
settings like this. In fact, using the cubic root of the volumes to sug-
gest a new threshold for LDs would be fallacious in the context we
studied because the new value would fall well within the range for
noise of auto-SLDs.
Volumes outperformed auto-SLD despite the fact that image resolu-
tion was not high by current standards. Had we strived for higher image
resolution and tighter quality control, we would have, according to
mounting evidence, reduced variance even further [12]. Because image
Figure 2. Kaplan-Meier curves of PR. Kaplan-Meier curves show that using average changes in volume (black solid line) instead of
average changes in auto-SLD (black dashed line) as the basis for categorical response classifies significantly more patients as partial
responders (PR). The Kaplan-Meier curves in gray represent volumetric responses produced by each of the seven independent image
analysis teams. There appear to be fewer than seven gray curves because there was so much overlap between teams. Censoring events
are shown as (+).
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quality in many standard-of-care settings has already surpassed what
was produced in the parent multinational trial from which we drew
these cases, VIA should be effective in many new clinical trials and,
eventually, in many clinical practice settings.
The variance in this project is probably not as low as what can be
achieved in many research settings. This is not surprising, as few
instructions were given to the image analysts, and there was no trial-
specific training. Indeed, the dendrogramatic analysis of systematic bias
suggests that human judgment is a major contributor to variance.
Nevertheless, the level of consistency in rank order among image anal-
ysis teams was highly similar, regardless of whether the end point was
whole tumor volume or auto-SLD. This finding is encouraging because
it suggests that biases can be characterized before trials begin with train-
ing cases like these. Pretrial identification of bias can increase our
understanding of the causes of variance, especially the components
due to judgments by image analysts. These biases can then be mini-
mized. Reader training that reduces bias should increase the interrater
measurement reproducibility. As a consequence, this should increase
the sensitivity of VIA as a key method for monitoring changes in tumor
mass and their responses to therapeutic interventions in both clinical
and experimental settings [31].
Although the sample size was small, our results are encouraging.
They were based on over 6000 measurements of tumor volume and
their corresponding auto-LDs by the seven teams, which might be
enough to begin suggesting that there is a context in which multiple
image analysts working independently can agree on the magnitude of
relatively small-to-moderate changes in tumor volumes. Agreement
might have been higher if the effects of treatment had been greater.
Of course, measures of performance could have been worse if the tumor
changes were smaller, if the tumors were evenmore complex in shape, if
contrast was decreased even further by surrounding pathology, and for
other reasons. Nevertheless, the challenge these cases presented suggests
that even advanced lung cancer can be a favorable disease setting for
quantifying volumes. Although consistent replication in larger samples
and whole clinical trials will be required to qualify the methodology, the
findings suggest that volumes might be more robust than auto-SLDs as
inputs for RECIST in other neoplastic diseases as well, especially when
tumor morphology and contrast are favorable.
This pilot study suggests that value is reproducible with a variety
of software tools. Using volumes as the basis for RECIST should im-
prove decision making, both in the care of individual patients and in
the management of clinical trials. The increased sensitivity provided
by whole tumor volumes could lead to an important paradigm shift,
especially in settings where patients have multiple options for alter-
native treatments. When relying on manually measured SLDs, rela-
tively large sample sizes are sometimes needed to determine whether
a new treatment is biologically active and deserves to be advanced in
development. VIA could reduce the number of subjects required, as
well as the time-on-trial per subject and, as a result, either speed the
advancement of promising treatments toward the market or hasten the
elimination of not-so-promising treatments. VIA could also enhance
RECIST-based assessment strategies in clinical settings because the
greater sensitivity for diagnosing disease progression could benefit
individual patients who have treatment alternatives available to them.
In these situations, VIA could well serve all stakeholders in the treat-
ment of cancer.
Figure 3. Kaplan-Meier curves of PD. Kaplan-Meier curves show that average changes in volume (black solid lines) perform significantly
better than average changes in auto-SLD (black dashed lines) for classifying PD. For volumes, a response of PD represents an increase of
+25%; for auto-SLDs, the standard RECIST value of +20% is shown. Kaplan-Meier curves in gray represent the response assessments
for PD produced by the individual image analysis teams. Censoring events are shown as (+).
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